natgillin/translations-raw huggingface dataset:
A meta-analysis of patients with moderate to severe Alzheimer's disease (MMSE total scores <20) from the six phase III, placebo-controlled, 6-month studies (including monotherapy studies and studies with patients on a stable dose of acetylcholinesterase inhibitors) showed that there was a statistically significant effect in favour of memantine treatment for the cognitive, global, and functional domains. 
Metaanaliza bolesnika s umjerenom do teškom Alzheimerovom bolešću (ukupni MMSE < 20) iz šest faza III placebom kontroliranih ispitivanja u trajanju od 6 mjeseci (uključujući monoterapijska ispitivanja i ispitivanja s bolesnicima na stabilnoj dozi inhibitora acetilkolinesteraze) pokazala je da postoji statistički značajan učinak u korist liječenja memantinom u kognitivnom, globalnom i funkcionalnom području.
When daily doses of 5 to 30 mg were administered, a mean cerebrospinal fluid (CSF)/serum ratio of 0.52 was calculated. 
Pri primjeni dnevnih doza od 5 do 30 mg izračunat je srednji omjer cerebrospinalni likvor (CSL)/serum od 0,52.
Constipation Vomiting Pancreatitis2 
Nepoznato konstipacija povraćanje pankreatitis2
HDPE (high-density polyethylene) bottles with PP (polypropylene) caps Pack sizes of 100 film-coated tablets. 
Bočice od HDPE (polietilen visoke gustoće) sa polipropilenskim zatvaračima Veličine pakiranja od 100 filmom obloženih tableta.
● other NMDA-antagonists at the same time should be avoided. 
• ostalih antagonista NMDA.
Elevated liver function test Hepatitis 
Često Nepoznato povišeni rezultat testa jetrene funkcije hepatitis
● ketamine (a substance generally used as an anaesthetic), 
• ketamin (tvar koja se obično koristi kao anestetik)
If you suffer from renal impairment (kidney problems), your doctor should closely monitor your kidney function and if necessary adapt the memantine doses accordingly. 
Ako imate oštećenje bubrega (problemi s bubrezima), liječnik treba pažljivo pratiti funkciju Vaših bubrega i ovisno o njoj prilagoditi dozu memantina, ako je to potrebno.
Memantine ratiopharm belongs to a group of medicines called NMDA-receptor antagonists. 
Memantin ratiopharm spada u skupinu lijekova poznatih kao antagonisti NMDA receptora.
● neuroleptics (substances used in the treatment of mental disorders) 
• neuroleptika (lijekovi koji se koriste za liječenje mentalnih poremećaja)
● Tiredness, fungal infections, confusion, hallucinations, vomiting, abnormal gait, heart failure and venous blood clotting (thrombosis/thromboembolism) 
• umor, gljivične infekcije, smetenost, halucinacije, povraćanje, poremećaj hoda, zatajenje srca i zgrušavanje venske krvi (tromboza/tromboembolija).
This is increased to one tablet once a day (1x 10 mg) in the second week and to one and a half tablets once a day in the third week. 
Ova doza se povećava na jednu tabletu jedanput na dan (1 x 10 mg) u drugom tjednu te na jednu i pol tabletu jedanput na dan u trećem tjednu.
Furthermore, Memantine ratiopharm has minor to moderate influence on the ability to drive and use machines such that outpatients should be warned to take special care. 
Nadalje, Memantin ratiopharm blago do umjereno utječe na sposobnost upravljanja vozilima i rada sa strojevima pa ambulantne bolesnike treba upozoriti da na to obrate posebnu pozornost.
Daily doses of 20 mg lead to steady-state plasma concentrations of memantine ranging from 70 to 150 ng/ml (0.5-1 μmol) with large interindividual variations. 
Dnevne doze od 20 mg dovode do plazmatskih koncentracija memantina u stanju dinamičke ravnoteže u rasponu od 70 do 150 ng/ml (0,5-1 µmol) s velikim interindividualnim razlikama.
Memantine ratiopharm contains soya lecithin, see section 4.3. 
Memantin ratiopharm sadrži sojin lecitin, vidjeti dio 4.3.
Memantine-treated patients showed a statistically significantly better effect than placebo-treated patients on the primary endpoints: Alzheimer's disease assessment scale (ADAS-cog) (p=0.003) and CIBIC-plus (p=0.004) at week 24 (last observation carried forward (LOCF)). 
Bolesnici liječeni memantinom pokazali su statistički značajno bolji učinak nego bolesnici koji su primali placebo u pogledu primarnih ishoda: skala procjene Alzheimerove bolesti (ADAS-cog) (p=0,003) i CIBIC-plus (p=0,004) u 24. tjednu liječenja (zadnje opažanje preneseno nadalje (LOCF)).
On the basis of the clinical studies, the recommended dose for patients over the age of 65 years is 20 mg per day (20 mg once a day) as described above. 
Temeljem kliničkih ispitivanja, preporučena doza za bolesnike starije od 65 godina iznosi 20 mg dnevno (20 mg jedanput na dan), kao što je gore opisano.
Memantine ratiopharm is used for the treatment of patients with moderate to severe Alzheimer's disease. 
Memantin ratiopharm se koristi za liječenje bolesnika s umjerenom do teškom Alzheimerovom bolešću.
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician´s interview based impression of change (CIBIC-plus): p=0.025; Alzheimer's disease cooperative study - activities of daily living (ADCS-ADLsev): p=0.003; severe impairment battery (SIB): p=0.002). 
U 6. mjesecu ispitivanja pokazani su povoljni učinci liječenja memantinom u usporedbi s placebom (analiza opaženih slučajeva za promjene bazirane na dojmu kliničara nakon intervjua (CIBIC-plus): p=0,025; kooperativno ispitivanje Alzheimerove bolesti - aktivnosti svakodnevnog života (ADCS-ADLsev): p=0,003; skup znakova teške onesposobljenosti (SIB, engl. severe impairment battery): p=0,002).
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu. 
Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranici Europske Agencije za lijekove: http://www.ema.europa.eu.
In clinical trials in mild to severe dementia, involving 1,784 patients treated with memantine and 1,595 patients treated with placebo, the overall incidence rate of adverse reactions with memantine did not differ from those with placebo; the adverse reactions were usually mild to moderate in severity. 
U kliničkim ispitivanjima blage do teške demencije, u kojima je 1784 bolesnika liječeno memantinom, a 1595 ih je dobivalo placebo, sveukupna stopa incidencije nuspojava u skupini liječenoj memantinom nije se razlikovala od stope incidencije nuspojava u skupini koja je primala placebo.
The recommended dose of Memantine ratiopharm for adults and older patients is 20 mg once a day. 
Preporučena doza Memantin ratiopharma za odrasle i starije bolesnike je 20 mg jedanput na dan.
Week 3 (day 15-21): 
3. tjedan (15.-21. dan):
Week 4 (day 22-28): 
4. tjedan (22.-28. dan):
The patient should take two 10 mg film-coated tablets (20 mg) or one 20 mg film-coated tablet per day. 
bolesnik treba uzimati dvije filmom obložene tablete od 10 mg (20 mg) ili jednu filmom obloženu tabletu od 20 mg dnevno.
Week 1 (day 1-7): 
1. tjedan (1.-7. dan):
Uncommon (affects 1 to 10 users in 1,000): 
Manje česte (javljaju se kod 1 do 10 na 1000 korisnika):
In these situations the treatment should be carefully supervised, and the clinical benefit of Memantine ratiopharm reassessed by your doctor on a regular basis. 
U tim slučajevima liječenje mora biti pažljivo nadzirano, a liječnik treba redovito ponovno procjenjivati kliničku korist od uzimanja Memantin ratiopharm.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu. 
Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranici Europske Agencije za lijekove http://www.ema.europa.eu.
In order to reduce the risk of side effects this dose is achieved gradually by the following daily treatment scheme: 
Kako bi se smanjio rizik od nuspojava ta doza se postiže postupno, pridržavajući se sljedeće sheme dnevnog liječenja:
In order to reduce the risk of side effects this dose is achieved gradually by the following daily treatment scheme. 
Kako bi se smanjio rizik od nuspojava ta doza se postiže postupno, pridržavajući se sljedeće sheme dnevnog liječenja.
Other medicines and Memantine ratiopharm 
Drugi lijekovi i Memantin ratiopharm
What you need to know before you take Memantine ratiopharm 
Što morate znati prije nego počnete uzimati Memantin ratiopharm
Do not use this medicine after the expiry date which is stated on the carton and the blister pack after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kartonskoj kutiji i blisterpakiranju iza oznake “Rok valjanosti” / “EXP”.
Memantine ratiopharm acts on these NMDA-receptors improving the transmission of nerve signals and the memory. 
Memantin ratiopharm djeluje na navedene NMDA receptore poboljšavajući prijenos živčanih signala i pamćenje.
In patients with mildly impaired renal function (creatinine clearance 50-80 ml/min) no dose adjustment is required. 
Kod bolesnika s blagim oštećenjem funkcije bubrega (klirens kreatinina 50-80 ml/min) nije potrebna prilagodba doze.
20 mg film-coated tablets 
20 mg filmom obložene tablete
STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 5 mg or 10 mg or 15 mg or 20 mg of memantine hydrochloride equivalent to 4.15 mg or 8.31 mg or 12.46 mg or 16.62 mg memantine. 
Jedna filmom obložena tableta sadrži 5 mg ili 10 mg ili 15 mg ili 20 mg memantinklorida, što odgovara 4,15 mg ili 8,31 mg ili 12,46 mg ili 16,62 mg memantina.
Week 2 (day 8-14): 
2. tjedan (8.-14. dan):
If you forget to take Memantine ratiopharm 
Ako ste zaboravili uzeti Memantin ratiopharm
In a study using orally administered 14C-memantine, a mean of 84% of the dose was recovered within 
U ispitivanju u kojem je korišten oralno primijenjen 14C-memantin, uklonjeno je prosječno 84% doze unutar 20 dana, više od 99% izlučeno je putem bubrega.
● If you take a large overdose of Memantine ratiopharm, contact your doctor or get medical advice, 
• Ako ste uzeli preveliku dozu Memantin ratiopharma, javite se Vašem liječniku za savjet, jer bi
When patients were identified with concurrent worsening in all three domains, results showed a statistically significant effect of memantine in preventing worsening, as twice as many placebo-treated patients as memantine-treated patients showed worsening in all three domains (21% vs. 11%, p<0.0001). 
Kada je ustanovljeno istodobno pogoršanje stanja bolesnika u sva tri područja, rezultati su pokazali statistički značajan učinak memantina u sprječavanju pogoršanja, u skupini bolesnika liječenih placebom bilo je dvostruko više pogoršanja u sva tri područja nego u skupini bolesnika liječenih memantinom (21% naspram 11%, p < 0,0001).
Common Common Uncommon Very rare 
Manje često Manje često
15 mg tablet week 4 and beyond 20 mg tablets once a day 
3. tjedan tableta od 15 mg 4. tjedan i nadalje tableta od 20 mg jednom dnevno
LIST OF EXCIPIENTS Contains lactose and soya lecithin. 
POPIS POMOĆNIH TVARI Sadrži laktozu i sojin lecitin.
What Memantine ratiopharm is and what it is used for 
Što je Memantin ratiopharm i za što se koristi
A pivotal monotherapy study in a population of patients suffering from moderate to severe Alzheimer's disease (mini mental state examination (MMSE) total scores at baseline of 3-14) included a total of 252 outpatients. 
Pivotalno ispitivanje monoterapije u populaciji bolesnika koji pate od umjerene do teške Alzheimerove bolesti (početne vrijednosti kratkog testa određivanja mentalnog statusa (MMSE) bile su 3-14) uključivalo je ukupno 252 ambulantna bolesnika.
The patient should take half a 10 mg film-coated tablet (5 mg) per day for 7 days. 
bolesnik treba uzimati polovicu filmom obložene tablete od 10 mg (5 mg) dnevno tijekom 7 dana.
Memantine ratiopharm contains lactose and soya lecithin This medicine contains lactose. 
Memantin ratiopharm sadrži laktozu i sojin lecitin Ovaj lijek sadrži laktozu.
Outer packaging for 4 week treatment initiation pack (28 tablets, week 1-4) 
Vanjsko pakiranje za 4-tjedno pakiranje za početak liječenja (28 tableta, 1.-4. tjedan)
Women taking Memantine ratiopharm should not breast-feed. 
Žene koje uzimaju Memantin ratiopharm ne bi trebale dojiti.
Week 3 (day 15-21): The patient should take one and a half 10 mg film-coated tablets (15 mg) per day for 7 days. 
3. tjedan (15.-21. dan): bolesnik treba uzimati jednu i pol filmom obloženu tabletu od 10 mg (15 mg) dnevno tijekom 7 dana.
The following Adverse Reactions listed in the Table below have been accumulated in clinical studies with memantine and since its introduction in the market. 
Sljedeće nuspojave koje su prikupljene tijekom kliničkih ispitivanja s memantinom i nakon stavljanja lijeka u promet su prikazane u tablici ispod.
Maintenance dose The recommended maintenance dose is 20 mg per day. 
Doza održavanja Preporučena doza održavanja je 20 mg na dan.
Week 2 (day 8-14): The patient should take one 10 mg film-coated tablet (10 mg) per day for 7 days. 
2. tjedan (8.-14. dan): bolesnik treba uzimati jednu filmom obloženu tabletu od 10 mg (10 mg) dnevno tijekom 7 dana.
Memantine ratiopharm contains lactose. 
Memantin ratiopharm sadrži laktozu.
10 film-coated tablets 14 film-coated tablets 21 film-coated tablets 28 film-coated tablets 30 film-coated tablets 42 film-coated tablets 50 film-coated tablets 56 film-coated tablets 98 film-coated tablets 100 film-coated tablets 112 film-coated tablets 
10 filmom obloženih tableta 14 filmom obloženih tableta 21 filmom obložena tableta 28 filmom obloženih tableta 30 filmom obloženih tableta 42 filmom obložene tablete 50 filmom obloženih tableta 56 filmom obloženih tableta 98 filmom obloženih tableta 100 filmom obloženih tableta 112 filmom obloženih tableta
● Headache, sleepiness, constipation, elevated liver function tests, dizziness, balance disorders, 
• glavobolja, pospanost, zatvor, povišeni rezultati testova jetrene funkcije, omaglica, poremećaji ravnoteže, nedostatak zraka, visoki krvni tlak i preosjetljivost na lijek.
10 film-coated tablets 14 film-coated tablets 21 film-coated tablets 28 film-coated tablets 30 film-coated tablets 42 film-coated tablets 56 film-coated tablets 98 film-coated tablets 100 film-coated tablets 
10 filmom obloženih tableta 14 filmom obloženih tableta 21 filmom obložena tableta 28 filmom obloženih tableta 30 filmom obloženih tableta 42 filmom obložene tablete 56 filmom obloženih tableta 98 filmom obloženih tableta 100 filmom obloženih tableta
In patients with severe renal impairment (creatinine clearance 5-29 ml/min) daily dose should be 10 mg per day. 
Kod bolesnika s teškim oštećenjem bubrega (klirens kreatinina 5-29 ml/min) dnevna doza bi trebala biti 10 mg dnevno.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer packaging (Blister) 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU Vanjsko pakiranje (blister)
In patients with moderate renal impairment (creatinine clearance 30-49 ml/min) daily dose should be 10 mg per day. 
Kod bolesnika s umjerenim oštećenjem bubrega (klirens kreatinina 30-49 ml/min), dnevna doza bi trebala biti 10 mg na dan.
Shelf life after first opening of the container: 6 months 
Rok valjanosti nakon prvog otvaranja: 6 mjeseci
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted prescription (see Annex I: Summary of Product Characteristics, section 4.2). 
Lijek se izdaje na ograničeni recept (vidjeti Prilog I.: Sažetak opisa svojstava lijeka, dio 4.2).
Administration of Memantine ratiopharm is not recommended in patients with severe hepatic impairment. 
Ne preporučuje se primjena Memantin ratiopharma kod bolesnika s teškim oštećenjem jetre.
EXP Shelf life after first opening: 6 months. 
Rok valjanosti nakon prvog otvaranja: 6 mjeseci.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer packaging (HDPE bottle) 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU Vanjsko pakiranje (HDPE bočica)
EU/1/13/836/013 10 film-coated tablets EU/1/13/836/014 14 film-coated tablets EU/1/13/836/015 21 film-coated tablets EU/1/13/836/016 28 film-coated tablets EU/1/13/836/017 30 film-coated tablets EU/1/13/836/018 42 film-coated tablets EU/1/13/836/019 56 film-coated tablets EU/1/13/836/020 98 film-coated tablets EU/1/13/836/021 100 film-coated tablets 
EU/1/13/836/013 10 filmom obloženih tableta EU/1/13/836/014 14 filmom obloženih tableta EU/1/13/836/015 21 filmom obložena tableta EU/1/13/836/016 28 filmom obloženih tableta EU/1/13/836/017 30 filmom obloženih tableta EU/1/13/836/018 42 filmom obložene tablete EU/1/13/836/019 56 filmom obloženih tableta EU/1/13/836/020 98 filmom obloženih tableta EU/1/13/836/021 100 filmom obloženih tableta
Memantine ratiopharm should be administered orally once a day. 
Memantin ratiopharm treba primjenjivati kroz usta jedanput na dan.
NAME OF THE MARKETING AUTHORISATION HOLDER ratiopharm 
NAZIV NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET ratiopharm
No adverse reactions of memantine were noted on male and female fertility. 
Nuspojave memantina vezane za plodnost muškaraca ili žena nisu bile opažene.
EU/1/13/836/001 10 film-coated tablets EU/1/13/836/002 14 film-coated tablets EU/1/13/836/003 21 film-coated tablets EU/1/13/836/004 28 film-coated tablets EU/1/13/836/005 30 film-coated tablets EU/1/13/836/006 42 film-coated tablets EU/1/13/836/007 50 film-coated tablets EU/1/13/836/008 56 film-coated tablets EU/1/13/836/009 98 film-coated tablets EU/1/13/836/010 100 film-coated tablets EU/1/13/836/011 112 film-coated tablets 
EU/1/13/836/001 10 filmom obloženih tableta EU/1/13/836/002 14 filmom obloženih tableta EU/1/13/836/003 21 filmom obložena tableta EU/1/13/836/004 28 filmom obloženih tableta EU/1/13/836/005 30 filmom obloženih tableta EU/1/13/836/006 42 filmom obložene tablete EU/1/13/836/007 50 filmom obloženih tableta EU/1/13/836/008 56 filmom obloženih tableta EU/1/13/836/009 98 filmom obloženih tableta EU/1/13/836/010 100 filmom obloženih tableta EU/1/13/836/011 112 filmom obloženih tableta
● anticholinergics (substances generally used to treat movement disorders or intestinal cramps) 
• antikolinergika (lijekovi koje se uglavnom koriste za liječenje poremećaja kretanja ili crijevnih grčeva) antikonvulziva (lijekovi koji se koriste za sprječavanje i ublažavanje napadaja)
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING Label (HDPE bottle) 
PODACI KOJI SE MORAJU NALAZITI NA UNUTARNJEM PAKIRANJU Naljepnica (HDPE bočica)
In postmarketing experience these reactions have been reported in patients treated with memantine. 
Ove su nuspojave prijavljene u postmarketinškom razdoblju kod bolesnika liječenih memantinom.
QUALITATIVE AND QUANTITATIVE COMPOSITION Memantine ratiopharm 10 mg 
KVALITATIVNI I KVANTITATIVNI SASTAV Memantin ratiopharm 10 mg
QUALITATIVE AND QUANTITATIVE COMPOSITION Memantine ratiopharm 5 mg 
KVALITATIVNI I KVANTITATIVNI SASTAV Memantin ratiopharm 5 mg
The use of medicinal products called 
Trebalo bi izbjegavati istodobnu primjenu lijekova koji se zovu
What Memantine ratiopharm contains - The active substance is memantine hydrochloride. 
Što Memantin ratiopharm sadrži - Djelatna tvar je memantinklorid.
Do not take Memantine ratiopharm: 
Nemojte uzimati Memantin ratiopharm
Memantine ratiopharm 5 mg Memantine ratiopharm 10 mg Memantine ratiopharm 15 mg Memantine ratiopharm 20 mg 
Memantin ratiopharm 5 mg Memantin ratiopharm 10 mg Memantin ratiopharm 15 mg Memantin ratiopharm 20 mg
Nervous system disorders 
Poremećaji živčanog sustava Često Često
Memantine ratiopharm contains the active substance memantine hydrochloride. 
Memantin ratiopharm sadrži djelatnu tvar memantinklorid.
Cellulose microcrystalline (E 460), starch pregelatinised (E 1404), lactose anhydrous, colloidal anhydrous silica (E 551), magnesium stearate (E 470b). 
Jezgra tablete mikrokristalična celuloza (E 460), prethodno geliran škrob (E 1404), bezvodna laktoza, koloidni bezvodni silicijev dioksid (E 551), magnezijev stearat (E 470b).
Take only one tablet per day Week 1 
Uzmite samo jednu tabletu na dan 1. tjedan
PVC/PVDC-Aluminium foil blister packs Pack sizes of 10, 14, 21, 28, 30, 42, 50, 56, 98, 100, 112 film-coated tablets. 
Blister pakiranja od PVC/PVDC-aluminijska folija Veličine pakiranja od 10, 14, 21, 28, 30, 42, 50, 56, 98, 100, 112 filmom obloženih tableta.
Memantine ratiopharm is available in packs of 10, 14, 21, 28, 30, 42, 56, 98 and 100 film-coated tablets. 
Memantin ratiopharm dostupan je u pakiranjima 10, 14, 21, 28, 30, 42, 56, 98 i 100 filmom obloženih tableta.
PVC/PVDC-Aluminium foil blister packs Pack sizes of 10, 14, 21, 28, 30, 42, 56, 98, 100 film-coated tablets. 
Blister pakiranja od PVC/PVDC-aluminijska folija Veličine pakiranja od 10, 14, 21, 28, 30, 42, 50, 56, 98, 100 filmom obloženih tableta.
Polysorbate 80 (E 433), polyvinyl alcohol (E 1203), titanium dioxide (E 171), talc (E 553b), soya lecithin (E 322), xanthan gum (E 415). 
Polisorbat 80 (E 433), poli(vinilni alkohol) (E 1203), titanijev dioksid (E 171), talk (E 553b), sojin lecitin (E 322), ksantanska guma (E 415).
PVC/PVDC-Aluminium foil blister packs Pack sizes of 28 (7 +7 +7 + 7) film-coated tablets. 
Veličine pakiranja od 28 (7 + 7 + 7 + 7) filmom obloženih tableta.
Memantine ratiopharm is available in packs of 10, 14, 21, 28, 30, 42, 50, 56, 98, 100 and 112 filmcoated tablets. 
Memantin ratiopharm dostupan je u pakiranjima 10, 14, 21, 28, 30, 42, 50, 56, 98, 100 i 112 filmom obloženih tableta.
What Memantine ratiopharm looks like and contents of the pack The 5 mg film-coated tablets are white to off-white, capsule shaped, biconvex tablets plain on one side and debossed with “5” on the other side. 
Kako Memantin ratiopharm izgleda i sadržaj pakiranja Filmom obložene tablete od 5 mg su bijele do gotovo bijele, bikonveksne tablete u obliku kapsule, glatke s jedne strane i s utisnutim “5” s druge strane.
Memantine ratiopharm 20 mg 
Memantin ratiopharm 20 mg
Polysorbate 80 (E 433) Polyvinyl alcohol (E 1203) Titanium dioxide (E 171) Talc (E 553b) Soya lecithin (E 322) Xanthan gum (E 415) 
Ovojnica polisorbat 80 (E 433) poli(vinilni alkohol) (E 1203) titanijev dioksid (E 171) talk (E 553b) sojin lecitin (E 322) ksantanska guma (E 415)
Cellulose microcrystalline (E 460) Starch pregelatinised (E 1404) Lactose anhydrous Colloidal anhydrous silica (E 551) Magnesium stearate (E 470b) 
Jezgra tablete mikrokristalična celuloza (E 460), prethodno gelirani škrob (E 1404), bezvodna laktoza, koloidni bezvodni silicijev dioksid (E 551), magnezijev stearat (E 470b).
Take only one tablet per day Week 4 
Uzmite samo jednu tabletu na dan 4. tjedan
PHARMACEUTICAL FORM AND CONTENTS Film-coated tablet 
OBLIK I SADRŽAJ Filmom obložena tableta 7 filmom obloženih tableta
Take only one tablet per day Week 2 
Uzmite samo jednu tabletu na dan 2. tjedan
Memantine ratiopharm 5 mg 
Memantin ratiopharm 5 mg
Take only one tablet per day Week 3 
Uzmite samo jednu tabletu na dan 3. tjedan
Lactose (40 mg/film-coated tablet) and soya lecithin (0.065 mg/film-coated tablet). 
Laktoza (40 mg/filmom obloženoj tableti) i sojin lecitin (0,065 mg/filmom obloženoj tableti).
Venous thrombosis/thromboembolism 
Često Manje često hipertenzija venska tromboza/tromboembolija
What is Memantine ratiopharm used for 
Za što se Memantin ratiopharm koristi
How to take Memantine ratiopharm 
Kako uzimati Memantin ratiopharm
Memantine ratiopharm 15 mg 
Memantin ratiopharm 15 mg
Memantine ratiopharm 10 mg 
Memantin ratiopharm 10 mg
INFORMATION IN BRAILLE Memantine ratiopharm 20 mg 
16. PODACI NA BRAILLEOVOM PISMU Memantin ratiopharm 20 mg
What Memantine ratiopharm looks like and contents of the pack White to off-white, capsule shaped, biconvex tablets with a break score on one side and debossed with “20” on the other side. 
Kako Memantin ratiopharm izgleda i sadržaj pakiranja Bijele do gotovo bijele, bikonveksne tablete u obliku kapsule, s razdjelnom crtom na jednoj strani i utisnutim “20” na drugoj strani.
Lactose (120 mg/film-coated tablet) and soya lecithin (0.195 mg/film-coated tablet). 
Laktoza (120 mg/filmom obloženoj tableti) i sojin lecitin (0,195 mg/ filmom obloženoj tableti).
MARKETING AUTHORISATION NUMBER(S) EU/1/13/836/022 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/13/836/022
Lactose (80 mg/film-coated tablet) and soya lecithin (0.13 mg/film-coated tablet). 
Laktoza (80 mg/filmom obloženoj tableti) i sojin lecitin (0,13 mg/filmom obloženoj tableti).
MARKETING AUTHORISATION NUMBER(S) EU/1/13/836/023 
BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/13/836/023